Skip to content

Prognostic Prediction of High-Grade Serous Ovarian Cancer Using Ultrasound O-RADS Classification Combined with Raman Spectroscopy

Prognostic Prediction of High-Grade Serous Ovarian Cancer Using Ultrasound O-RADS Classification Combined with Raman Spectroscopy

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600126075
Enrollment
Unknown
Registered
2026-06-03
Start date
2026-06-08
Completion date
Unknown
Last updated
2026-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

High-Grade Serous Ovarian Cancer

Interventions

Platinum-resistant group and Platinum-sensitive group:None

Sponsors

Harbin Medical University Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >= 18 years; 2. Pathologically confirmed high-grade serous ovarian carcinoma (HGSOC); 3. Completion of pre-treatment ultrasound examination with imaging data available for standardized retrospective O-RADS classification; 4. Receipt of standardized postoperative treatment, as documented in medical records; 5. Availability of fresh-frozen or formalin-fixed paraffin-embedded (FFPE) tumor tissue samples in the hospital pathology department; 6. Relatively complete clinical data.

Exclusion criteria

Exclusion criteria: 1. Non-ovarian primary malignancies or non–high-grade serous ovarian carcinoma (HGSOC); 2. Presence of other concomitant malignancies or hematologic disorders; 3. Incomplete imaging data or insufficient tissue sample quality for Raman spectroscopic analysis; 4. Severe missing clinical data or inability to obtain follow-up outcome information.

Design outcomes

Primary

MeasureTime frame
Overall Survival;Progression-Free Survival;

Secondary

MeasureTime frame
O-RADS Classification;Raman Spectroscopy Features (peak intensity, peak position, peak ratio, etc.);Serum Biomarkers (e.g., CA125, HE4);

Countries

China

Contacts

Public ContactDai Shaochun

Harbin Medical University Cancer Hospital

490665324@qq.com+86 192 5451 1434

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 11, 2026